Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 2/3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Thrombocythemia, Essential 2Polycythemia Vera 2Primary Myelofibrosis 1Melanoma 1Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 8Cyclophosphamide 8Methotrexate 7Peripheral Blood Stem Cell Transplantation 6Interferon-alpha 6Hydroxyurea 6bosutinib 5asciminib 5Whole-Body Irradiation 5Mycophenolic Acid 5Tacrolimus 4Dasatinib 4Busulfan 4peginterferon alfa-2a 3fludarabine phosphate 3fludarabine 3Radiotherapy 3Cyclosporine 3sargramostim 2ponatinib 2Sirolimus 2Idarubicin 2Etoposide 2BID protein, human 2thymoglobulin 1peginterferon alfa-2b 1pegaspargase 1olverembatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × peginterferon alfa-2a × Clear all
NCT02201459 2025-10-02

PETALs

Hospices Civils de Lyon

Phase 3 Completed
200 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02381379 2020-09-14

MSIT

Ministry of Health, Malaysia

Phase 3 Unknown
118 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02736721 2016-09-20

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

Hoffmann-La Roche

Phase 3 Completed
41 enrolled 8 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡